tyb
Schrödinger, Inc sold by Bill and Melinda Gates Foundation: $129.48-August 14 & 17
Schrödinger Announces Closing of Public Offering
Schrödinger, Inc. whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $66.00 per share. The offering consisted of 5,250,000 shares sold by the Company, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, and 500,000 shares sold by a selling stockholder. The gross proceeds to the Company in the offering were $346.5 million. The Company did not receive any of the proceeds from the sale of the shares by the selling stockholder. Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets acted as joint book-running managers for the offering.
https://www.marketscreener.com/quote/stock/SCHRODINGER-INC-102588712/news/Schrodinger-Schrodinger-Announces-Closing-of-Public-Offering-31133398/
co-founder sold $31.02m yesterday
https://www.finviz.com/insidertrading.ashx?oc=1798426&tc=7
Schrodinger, Inc. provides computational software solutions for drug discovery to the biopharmaceutical industry. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. Its platform integrates solutions for predictive modeling, data analytics and collaboration. Its wholly-owned programs include SDGR1, SDGR2, SDGR3, SDGR4 and SDGR5. SDGR1 and SDGR2 drug discovery programs are focused on targets that mediate deoxyribonucleic acid (DNA) repair, cell cycle regulation, replication stress responses, and apoptosis, or programmed cell death. SDGR3, SDGR4 and SDGR5 drug discovery programs are focused on genetically-defined cancers. Number of employees : 394 people.
Schrödinger's partners include larger pharmaceutical companies, including Takeda and Sanofi
https://www.marketscreener.com/quote/stock/SCHRODINGER-INC-102588712/company/
https://www.finviz.com/insidertrading.ashx?oc=1166559&tc=7&b=2
82-8000 and 92-9000 USAF VIP 747's continue en and CLUB22 USAF E-4B Nightwatch departed Davis-Monthan AFB after leading 92-9000 in earlier today
09-0017 USAF C-32A departed Luke AFB, Phoenix en
02-5001 USAFSOC C-32B departed Idaho Falls Regional Airport se
nice